FDA’s First-of-its-Kind Approval for Melanoma Treatment: Game-Changing Therapy Offers New Hope to Patients
PHILADELPHIA, PA – The US Food and Drug Administration has approved a groundbreaking therapy that could potentially benefit patients with metastatic melanoma, a rare and deadly form of skin cancer. The therapy, known as Amtagvi, is developed by California-based company Iovance Biotherapeutics and is designed for patients who have not responded to other treatments or whose cancer is inoperable or has spread to other parts of the body. Amtagvi represents the first cellular therapy approved …